ACT Earnings Date: Nov 4, 2026 (Estimated) — Enact Holdings Inc.
NASDAQ · Financials · Insurance - Specialty
Updated
When is ACT's next earnings date?
Enact Holdings Inc. (ACT) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.19 on revenue of $317.9M.
How did ACT do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Enact Holdings Inc. posted EPS of $1.26 versus the $1.19 estimate, a beat of 5.0%. Revenue was $317.3M against a $315.8M estimate. The stock's 1-day post-earnings move was +1.8%.
How much does ACT stock move after earnings?
ACT beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.7% (up or down) in the day after earnings.
About Enact Holdings Inc.
Enact Holdings, Inc. operates as a private mortgage insurance company in the United States. The company engages in writing and assuming residential mortgage guaranty insurance. It also offers private mortgage insurance products insuring prime-based, individually underwritten residential mortgage loans; pool mortgage insurance; contract underwriting services; and mortgage-related reinsurance products. The company serves large money center banks, non-bank lenders, national and local mortgage bankers, community banks, and credit unions. The company was formerly known as Genworth Mortgage Holdings, Inc. and changed its name to Enact Holdings, Inc. in May 2021. Enact Holdings, Inc. was founded in 1981 and is headquartered in Raleigh, North Carolina. Enact Holdings, Inc. is a subsidiary of Genworth Holdings Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 1.19 | 1.26 | +5.00% | $317.3M | ✅ Beat | +1.76% | +3.24% | +4.01% |
| 2026-05-05 | Q1 2026 | 1.21 | 1.21 | +0.00% | $312.1M | ➖ Inline | +1.77% | +1.15% | -2.67% |
| 2026-02-03 | Q4 2025 | 1.10 | 1.23 | +11.82% | $312.7M | ✅ Beat | +9.27% | +5.44% | +3.20% |
| 2025-11-05 | Q3 2025 | 1.11 | 1.12 | +0.90% | $311.5M | ✅ Beat | +2.27% | +4.78% | +6.34% |
| 2025-07-30 | Q2 2025 | 1.11 | 1.15 | +3.60% | $304.9M | ✅ Beat | +0.98% | +5.16% | +9.79% |
| 2025-04-30 | Q1 2025 | 1.09 | 1.10 | +0.92% | $306.8M | ✅ Beat | +2.19% | +2.11% | -0.52% |
| 2025-02-04 | Q4 2024 | 1.03 | 1.09 | +5.83% | $301.8M | ✅ Beat | +1.45% | +0.53% | +1.11% |
| 2024-11-06 | Q3 2024 | 1.01 | 1.16 | +14.85% | $309.6M | ✅ Beat | -1.66% | +0.77% | +3.62% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY13 · $348.1M total
| Segment | Share | Revenue | YoY | Q1 FY12 | Q2 FY12 | Q3 FY12 | Q4 FY12 |
|---|---|---|---|---|---|---|---|
| Anda Distribution | 88.2% | $307.1M | — | — | — | — | — |
| Actavis Pharma | 7.2% | $24.9M | — | — | — | — | — |
| Actavis Specialty Brands | 4.6% | $16.1M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.